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ABSTRACT
Our objective was to evaluate the effect of the COX-2 inhibitor, celecoxib, 
on (1) proliferation and apoptosis in human ovarian cancer cell lines and primary 
cultures of ovarian cancer cells, and (2) inhibition of tumor growth in a genetically 
engineered mouse model of serous ovarian cancer under obese and non-obese 
conditions. Celecoxib inhibited cell proliferation in three ovarian cancer cell lines and 
five primary cultures of human ovarian cancer after 72 hours of exposure. Treatment 
with celecoxib resulted in G1 cell cycle arrest, induction of apoptosis, inhibition of 
cellular adhesion and invasion and reduction of expression of hTERT mRNA and COX-
2 protein in all of the ovarian cancer cell lines. In the KpB mice fed a high fat diet 
(obese) and treated with celecoxib, tumor weight decreased by 66% when compared 
with control animals. Among KpB mice fed a low fat diet (non-obese), tumor weight 
decreased by 46% after treatment with celecoxib. In the ovarian tumors from obese 
and non-obese KpB mice, treatment with celecoxib as compared to control resulted 
in decreased proliferation, increased apoptosis and reduced COX-2 and MMP9 protein 
expression, as assessed by immunohistochemistry. Celecoxib strongly decreased the 
serum level of VEGF and blood vessel density in the tumors from the KpB ovarian 
cancer mouse model under obese and non-obese conditions. This work suggests that 
celecoxib may be a novel chemotherapeutic agent for ovarian cancer prevention and 
treatment and be potentially beneficial in both obese and non-obese women.
INTRODUCTION
Epithelial ovarian cancer (OC) is one of the most 
deadly cancers with an overall 5-year survival of only 30-
40% [1, 2]. Although most OC patients initially respond 
to surgical debulking followed by carboplatin/taxane 
chemotherapy, the vast majority of women will recur 
and succumb to their disease. More than 21,000 cases 
are diagnosed annually in the US, and more than 14,000 
women die in the same period [3]. Increasing evidence 
suggests that obesity is a significant risk factor for OC and 
is associated with worse outcomes for this disease [4–18]. 
Therefore, a metabolic approach to the treatment of OC 
may provide a novel strategy to improve outcomes for this 
invariably lethal disease.
Obesity induced inflammation leads to the 
induction of cyclooxygenase-2 (COX-2) expression and 
subsequent prostaglandin (PG) and pro-inflammatory 
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cytokines production, which may directly favor ovarian 
carcinogenesis. COX-2, the rate-limiting enzyme 
in prostaglandin synthesis, has been found to be 
overexpressed and associated with poor prognosis in a 
number of different cancers, including ovarian cancers 
[19]. COX-2 has been shown to affect tumor progression 
through the inhibition of apoptosis and the promotion 
of proliferation, angiogenesis, and invasion [20, 21]. 
Celecoxib is a selective COX-2 inhibitor in the NSAID 
class which is primarily used as an anti-inflammatory drug 
in the treatment of conditions such as rheumatoid arthritis, 
osteoarthritis or severe cases of dysmenorrhea [20–23]. 
Epidemiological studies have indicated that long term 
use of celecoxib may reduce the risk of carcinogenesis 
in breast, prostate, lung and liver cancer [20–23]. 
Celecoxib has been shown to have anti-proliferative and 
anti-tumorigenic effects in vitro and in vivo for a number 
of different cancers [20, 21]. Thus, our objective was 
to evaluate the effect of celecoxib, on (1) proliferation 
and apoptosis in ovarian cancer cell lines and primary 
cultures of ovarian cancer cells, and (2) inhibition of 
tumor growth in a genetically engineered mouse model 
of serous ovarian cancer under obese and non-obese 
conditions.
RESULTS
Effect of celecoxib on ovarian cancer cell 
proliferation, COX-2 expression and PEG2 
production
The effect of celecoxib on ovarian cancer cell 
proliferation was assessed by MTT assay. As shown in 
Figure 1A, celecoxib inhibited cell growth in the three 
ovarian cancer cell lines in a dose dependent manner after 
72 hours of exposure. The mean IC50 value for SKOV3, 
HEY and IGROV1 was 25, 44 and 50 uM (p = 0.0001-
0.0002), respectively.
All three ovarian cancer cell lines expressed COX-
2 (Figure 1B). Celecoxib significantly inhibited COX-2 
protein expression in a dose dependent manner in all three 
ovarian cancer cell lines, as demonstrated by Western 
immunoblotting (Figure 1C). In addition, celecoxib (1-
25 μM) significantly suppressed PEG2 production in the 
media in all three ovarian cancer cells after 18 hours of 
exposure (Figure 1D) (p < 0.05), as assessed by ELISA 
assay. Given that hTERT expression is thought to be a 
sensitive marker of telomerase function as well as cell 
proliferation, we next measured hTERT mRNA expression 
Figure 1: Celecoxib inhibited cell proliferation in ovarian cancer cell lines. The SKOV3, Hey and IGROV1 cells were cultured 
for 24 hours and then treated with celecoxib at indicated doses in 96 well plates for 72 hours. Cell proliferation was assessed by MTT assay 
A. The three ovarian cancer cell lines have varying levels of COX-2 protein expression, and the sensitivity to celecoxib do not relate to 
protein expression of COX-2 B. Western blotting results indicated that celecoxib inhibited COX-2 protein expression in a dose-dependent 
manner after 24 hours treatment C. Celecoxib decreased PGE2 production in the media in ovarian cancer cells after 18 hours treatment D. 
Real time PCR results showed that celecoxib reduced hTERT mRNA expression after 24 hours treatment E. (* < 0.05).
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in our three ovarian cancer cell lines by real-time RT-PCR. 
Treatment with celecoxib at varying concentrations (1 – 50 
μM) for 24 hours significantly decreased hTERT mRNA 
expression in a dose-dependent manner in the ovarian 
cancer cell lines (Figure 1E) (p < 0.05).
Celecoxib induces cell cycle arrest in G0/G1 and 
apoptosis
To evaluate the underlying mechanism of growth 
inhibition by celecoxib, the cell cycle profile was analyzed 
after treating the SKOV3, Hey and IGROV1 cell lines 
with varying doses of celecoxib (0.1-50 uM) for 24 hours. 
As shown in Figure 2A–2C, celecoxib induced G0/G1 
cell cycle arrest and reduced S phase in a dose-dependent 
manner in the ovarian cancer cell lines. Caspases play a 
central role in the induction of apoptosis. Caspase-3 is a 
member of the caspase family, which consists of cysteine 
proteases that act in a cascade manner to trigger apoptosis, 
and is considered to be one of the effector caspases 
involved in cell disassembly [24]. To determine whether 
caspases were involved in celecoxib-induced apoptosis in 
the ovarian cancer cell lines, cleaved caspase-3 activity 
was determined in the SKOV3, Hey and IGROV1 cell 
lines after treatment with celecoxib for 16 hours. As 
shown in Figure 2D, treatment with celecoxib (0.1–50 
μM) significantly induced caspase-3 activity by 1.7, 5.4 
and 3.8 fold at a dose of 50 uM compared to control in the 
SKOV3, Hey and IGROV1 cells (p < 0.05). These results 
suggest that celecoxib reduces cell proliferation through 
both the induction of cell cycle G1 arrest and apoptosis in 
ovarian cancer cells.
To further assess the possible role of apoptosis in 
celecoxib-treated ovarian cancer cells, we used the pan-
caspase inhibitor (Z-VAD-FMK) to block caspase activity 
along with celecoxib treatment. Cells were pretreated with 
Z-VAD-FAM at 20 um for 2 hours before treatment of 
celecoxib at 1 um for 16 hours. The results showed that 
pre-treatment with Z-VAD-FMK total blocked the caspase 
3 activity induced by celecoxib (Figure 2E). Furthermore, 
blocking caspase activation resulted in a significant 
decrease in celecoxib-mediated growth inhibition in all 
three ovarian cancer cell lines after 72 hours of treatment 
with celecoxib, suggesting that apoptosis may be a major 
mechanism for the inhibition of cell proliferation seen in 
celecoxib treated ovarian cancer cells (Figure 2F).
Effect of celecoxib on adhesion and invasion in 
ovarian cancer cells
To analyze the effect of celecoxib on adhesion 
and invasion in ovarian cancer cells, an in vitro laminin 
adhesion assay and ChemoTx invasion system were 
utilized, respectively. Cellular adhesion was decreased by 
20-40% in all three ovarian cancer cell lines at a dose of 25 
mM (p = 0.002-0.009) and at 50 mM (p = 0.00001-0.02), 
after 2 hours of treatment (Figure 3A). Three ovarian 
cancer cells treated with celecoxib at a dose 25 uM for 4 
Figure 2: Celecoxib induced cell cycle G1 arrest and apoptosis in ovarian cancer cells lines. The SKOV3, Hey and IGROV1 
cells were treated with celecoxib at the indicated dose for 24 hours and then analyzed for cell cycle distributions by flow cytometry. Cell 
cycle phase analysis is shown in SKOV3, Hey and IGROV1 as representative of one of three independent experiments A-C. Celecoxib 
induced the activity of cleave caspase-3 in the ovarian cancer cell lines after 16 hours of treatment D. Pretreatment with a pan-caspase 
inhibitor (Z-VAD-FMK) at 20 um for 2 hours totally blocks cleaved caspase 3 activity induced by celecoxib E. Blocking caspase activity 
with Z-VAD-FMK resulted in a decrease in celecoxib-mediated growth inhibition in the ovarian cancer cell lines F. (* < 0.05).
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hours resulted in a significantly decreased invasive ability 
of 39-69% (p<0.001) (Figure 3B). These results suggest 
that celecoxib reduces adhesion and invasion of ovarian 
cancer cells.
Celecoxib inhibits tumor growth in the KpB 
serous ovarian cancer mouse model
The KpB mice began the LFD (Low fat diet) or 
HFD (High fat diet) at 3 weeks of age and were divided 
into four groups (N = 15 mice per group), including LFD 
(non-obese) and HFD (obese) groups treated with either 
celecoxib or placebo. The initial average body weight of 
the obese mice when starting treatment with celecoxib (5 
mg/kg, 4 weeks) was 48.4 gm, while that of the non-obese 
mice was only 29.78 gm (p<0.01, data not shown).
Regular twice-weekly measurements yielded no 
changes in blood glucose or weight (data not shown) 
during celecoxib or placebo treatment. A substantial 
reduction in tumor growth and tumor weight was found in 
the celecoxib group in comparison with the placebo group 
(Figure 4A–4C). In the obese KpB mice, tumor weight 
decreased by 66% (p<0.05) with celecoxib treatment when 
compared with control-treated animals. Among non-obese 
KpB mice, tumor weight decreased by 46% after treatment 
with celecoxib (p<0.05) when compared with control-
treated animals. Serum PGE2 levels were significantly 
decreased by 30-40% in celecoxib-treated mice fed a high 
and low fat diet compared with the placebo control groups 
(p<0.01) (Figure 4D), suggesting that celecoxib suppresses 
the activity of COX-2 in the KpB mice.
After treatment with celecoxib or placebo, the 
protein expression of Ki-67, COX-2, cleaved caspase-3 
and matrix metalloproteinase-9 (MMP9) in the ovarian 
tumors was evaluated by immunohistochemistry (IHC) 
(Figure 4E). The expression of COX-2 was significantly 
reduced by 60% and 40% in the obese and non-obese 
groups treated with celecoxib compared with the control 
treated mice, respectively (p<0.01). Celecoxib inhibited 
Ki-67 expression, a marker of cell proliferation, in the 
treated mice on a high fat diet (obese) by 22% and those 
on a low fat diet (non-obese) by 11%. Celecoxib increased 
cleaved caspase-3 expression from 18-50% in the tumors 
from the obese group as compared to 8-22% in the non-
obese group, suggesting an enhanced effect of celecoxib 
on apoptosis in the setting of obesity. MMP9 has been 
implicated in invasion and metastasis in ovarian cancer. 
Celecoxib treatment reduced MMP9 expression by 27% 
in the obese group and by 20% in the non-obese group as 
compared to controls.
The effect of celecoxib on angiogenesis in 
ovarian cancer cells and tumors
VEGF is a key mediator of angiogenesis, a process 
that is important in ovarian cancer growth and metastasis. 
We investigated the effect of celecoxib in the inhibition of 
secretory VEGF, a pro-angiogenic factor responsible for 
the migration and invasion of ovarian cancer cells. VEGF 
secretion in serum-free culture media was assessed in all 
three ovarian cancer cell lines by ELISA after 24 hours of 
treatment. Celecoxib notably decreased VEGF secretion 
compared with controls in the SKOV3 and IGROV1 
cell lines, whereas celecoxib treatment did not show any 
significant change in the secreted VEGF levels in the Hey 
cell line (Figure 5A).
Serum levels of VEGF were found to be decreased 
significantly in the obese and non-obese KpB mice 
treated with celecoxib as compared to controls (Figure 
5B). The level of serum VEGF decreased by 20% in the 
ovarian tumors from obese mice and 27% in the ovarian 
tumors from non-obese mice. To further confirm the 
role of decreased VEGF activity induced by treatment 
with celecoxib in the formation of blood vessels, we 
analyzed the treated ovarian tumors through staining 
with the endothelial cell marker, CD31 (Figure 5C and 
Figure 3: Celecoxib inhibited cell adhesion and invasion in ovarian cancer cells lines. The ovarian cancer cells were treated 
with celecoxib at a range of dose from 0.1 -1 50 μM. Adhesion was assessed by laminin-1 assay after 2 hours of treatment with celecoxib 
A. Invasion was determined by ChemoTx invasion kit, after 4 hours of treatment with celecoxib B. (* < 0.05).
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5D). Ovarian tumors from the obese and non-obese mice 
treated with celecoxib had significantly reduced blood 
vessel density (23% in the obese group and 13% in the 
non-obese group), in comparison to placebo-treated mice.
Celecoxib inhibited proliferation of primary 
cultures of ovarian cancer cells
We next investigated the effects of celecoxib on 
cell growth in human primary cultures of ovarian cancer 
using the MTT assay. These tissue samples were obtained 
from patients undergoing surgery for primary ovarian 
cancer. After 72 hours of treatment, all five primary 
cultures responded to the celecoxib treatment, showing 
a significant level of cytotoxicity and inhibition of cell 
growth at a dose up to 50 uM with a range of IC50 values 
from 20-45 uM (Figure 6A). In order to determine if the 
level of COX-2 protein expression was related to the 
sensitivity to celecoxib in each primary culture case, 
we assessed COX-2 protein expression using Western 
blotting in the five untreated primary cell cultures. The 
results revealed varying levels of COX-2 expression in 
the five primary cultures (Figure 6B). An analysis of the 
data using a linear regression model showed the levels of 
COX-2 protein expression did not correlate to sensitivity 
to celcecoxib in the five primary ovarian cancer cultures.
DISCUSSION
Celecoxib has been shown to have anti-tumorigenic 
effects in various types of human cancer cells and animal 
models [21]. Treatment with celecoxib has been shown to act 
on multiple targets and pathways in cancer cells, including 
proliferation, apoptosis, angiogenesis, invasion and tumor-
induced immune suppression via COX-2 dependent and 
independent mechanisms [21, 25, 26]. COX-2 has been 
found to promote resistance to apoptosis and enhanced 
survival by regulating protein expression of NF-kB, 
SERCA, PDK-1/Akt, survivin, Bcl-2 and Mcl-1 [26–29]. It 
is thought that COX-2 inhibitors interfere with tumorigenesis 
and apoptosis through decreased PEG2 production, a 
prostaglandin product of COX-2 [29, 30]. High levels of 
COX-2 have been found to promote resistance to apoptosis 
by altering the relative protein levels of survivin and of the 
Bcl-2 family [30]. Conversely, decreased levels of COX-
2 protein expression and PGE2 as the result of celecoxib 
treatment have been correlated with increases in apoptosis 
in cancer cells [30]. These findings suggest that celecoxib is 
not simply blocking the function of COX-2 but may also be 
disrupting COX-2 protein production [30]. Further support 
of this is that the anti-apoptotic effects of COX-2 are better 
correlated to decreases in COX-2 protein expression than 
inhibition of enzymatic activity [26, 30].
Figure 4: Celecoxib inhibited tumor growth in a genetically engineered mouse model of serous ovarian cancer (KpB 
mouse model). The KpB mice were fed a HFD (obese) or LFD (non-obese) starting at 3 weeks of age. Once a 0.1x0.1 cm ovarian tumor 
was palpated, these mice underwent treatment with celecoxib (5 mg/kg) versus placebo for 4 weeks. Celecoxib significantly inhibited 
tumor volume and tumor weight A, B, and C. Celecoxib reduced the level of serum PGE2 in the HFD- and LFD-fed groups D. The effect 
of celecoxib on the cell proliferation index, COX-2, apoptosis and invasion was assessed through expression of Ki67, COX-2, cleaved 
caspase3, and MMP9, respectively, as evaluated through immunohistochemistry E. (* p< 0.05).
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We found that celecoxib treatment significantly 
reduced COX-2 protein expression and PGE2 production 
in ovarian cancer cell lines, primary cultures of ovarian 
cancer and the KpB ovarian cancer mouse model. 
Celecoxib decreased cell growth, increased cleaved 
caspase-3 activity and induced cell cycle G1 phase arrest 
in a dose-dependent manner in three ovarian cancer cell 
lines. At 72 hours of treatment with celecoxib, the IC50 
for SKOV3, IGROV1 and Hey cells was 25, 44 and 50 
uM, respectively, and five primary cultures of ovarian 
cancer had achievable IC50 values (between 20-45 uM). 
hTERT, a marker of proliferating cells [31, 32], was 
statistically decreased in all ovarian cancer cell lines 
treated with celecoxib. In addition, celecoxib inhibited 
ovarian tumor growth, induced apoptosis and reduced 
angiogenesis in obese and non-obese KpB mice. Our 
results are in agreement with those previously reported 
in ovarian cancer cell lines and xenograft models [27, 
33, 34], suggesting that celecoxib may have promise as a 
potential treatment for ovarian cancer.
Invasion and metastasis are the leading causes for 
recurrence, poor prognosis and death in ovarian cancer 
patients [35, 36]. Adhesion and invasion are early steps 
involved in the metastatic process for ovarian cancer, 
which has a complex molecular basis that likely involves 
adhesion molecules, cell surface receptors, oncogenes, 
chloride channels, fatty acid synthase and focal adhesion 
kinase [37, 38] Overexpression of COX-2 leads to 
phenotypic changes in cancer cells that may enhance their 
tumorigenic potential and invasive ability [39]. PGE2 
production also favors the migration of cancer cells to 
endothelial cells [40]. Several studies have reported that 
celecoxib inhibits adhesion and invasion in gastric cancer, 
oral cancer, lung cancer, colon cancer and osteosarcoma 
cells through multiple cell signaling pathways such as 
NF-kB, MMP-2/9, E-cadherin, β-catenin and Akt/PKB 
[41–43]. Among these, matrix metalloproteinases (MMPs) 
plays an important role in invasion and metastasis for a 
number of malignancies[44]. Overexpression of COX-2 
in lung cancer cells, through transfection with a COX-2 
expression vector, has been shown to result in increased 
Figure 5: Celecoxib inhibited angiogenesis in vitro and in vivo. Celecoxib reduced the production of VEGF in the media of SKOV3, 
Hey and IGROV1 cells A. after 24 hours of treatment and mouse serum from obese and non-obese KpB mice B. Immunohistochemistry 
results for CD31 indicated that celecoxib reduced the density of tumor blood vessels in the obese and non-obese KpB ovarian cancer model 
C and D. (*p<0.05).
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protein expression of MMPs and E-cadherin as well as 
corresponding enhanced invasion and migration abilities 
[45, 46]. Inhibition of COX-2 expression by celecoxib 
leads to decreased secretion of MMP-2 and MMP-9 and 
suppression of the metastatic potential in animal models 
[46]. In addition, treatment with PGE2 has been found to 
partially enhance cell migration and invasion in various 
types of human cancer cells [47]. We found that celecoxib 
significantly inhibited adhesion and invasion in all three 
ovarian cancer cells tested and reduced MMP9 protein 
expression, PGE2 production and blood vessel density in 
the ovarian tumors from obese and non-obese KpB ovarian 
mice, suggesting that celecoxib has both anti-tumorigenic 
and anti-metastatic effects in ovarian cancer.
Accumulating evidence suggests that obesity is a 
significant risk factor for ovarian cancer and is associated 
with worse outcomes for this disease [4–18]. Obesity 
leads to elevated expression of insulin, estrogen, growth 
factors, inflammatory cytokines and adipokines, which 
promote ovarian cancer cell proliferation, survival, 
metastasis, angiogenesis and reduced apoptosis in cancer 
cells. Obesity-associated inflammation is thought to be 
one of the most important factors connecting obesity to 
cancer [19, 48, 49]. Multiple lines of preclinical evidence 
demonstrate that COX-2 contributes to obesity and 
obesity-induced muscular insulin resistance [48]. COX-
2–derived PGE2 has been shown to up-regulate aromatase 
through a cAMP–protein kinase A (PKA) cascade in 
human breast tissue, and the production of COX-2–derived 
PGE2 in the breast tissue has been positively correlated 
with both obesity and breast inflammation in women [50]. 
Thus, these potential benefits of COX-2 inhibition provide 
a rationale for celecoxib’s use in ovarian treatment and 
prevention, specifically for high risk obese women with 
this disease [51, 52].
Although celecoxib has been shown to inhibit tumor 
growth in several animal cancer models, including ovarian 
cancer xenograft-bearing mice [27, 34], less is known of 
celecoxib’s impact on ovarian tumor growth in genetically 
engineered mouse models or in obese versus non-obese 
mice. In this study, we mimicked a clinically obese state of 
ovarian cancer by using the KpB ovarian cancer model and 
by feeding these mice either a LFD or HFD once the mice 
reached 3 weeks of age. Celecoxib inhibited the growth 
of ovarian cancer in obese and non-obese KpB mice 
without any noticeable toxicity. Treatment with celecoxib 
in the obese group appeared to have greater anti-tumor 
efficacy than in the LFD group when comparing tumor 
volume and tumor weight between the two groups (66% 
versus 46%, respectively) (Figure 5A–5C). Inhibition of 
ovarian tumor growth in both obese and non-obese mice 
was significantly associated with decreased levels of 
COX-2, MMP9 and Ki-67 protein expression, reduction 
of blood vessel density and increased apoptosis. Although 
the mechanisms by which celecoxib inhibits the growth of 
the tumor in vivo are currently unclear, our data suggests 
that celecoxib exerts its anti-tumorigenic effects in the 
KpB ovarian cancer mouse model via a COX-2-dependent 
pathway through induction of apoptosis, inhibition of 
tumor angiogenesis and reduction of the cell proliferation 
index.
Ovarian cancer growth is angiogenesis-dependent, 
and VEGF is the most potent and specific angiogenic 
growth factor. Overexpression of VEGF plays a pivotal 
role in angiogenesis, carcinogenesis and progression of 
ovarian cancer [53]. COX-2 has been found to stimulate 
angiogenesis by promoting the production of VEGF and 
by increasing products of PGE2 and prostacycline [54]. 
Overexpression of VEGF in primary tumor and serum is 
associated with poor progression-free survival (PFS) and 
overall survival (OS) for patients with ovarian cancer 
[54, 55]. Celecoxib strongly decreased the serum level 
of VEGF in the KpB ovarian cancer mouse models 
under obese and non-obese conditions. Treatment 
Figure 6: Celecoxib inhibited cell proliferation in primary cell cultures of human ovarian cancer. Five primary cell cultures 
of ovarian cancer were cultured in 96 well plates and treated with celecoxib as indicated doses for 72 hours. Cell proliferation was assessed 
by MTT assay A. COX-2 protein expression did not predict sensitivity to celecoxib in the primary cultures of ovarian cancer B. (*p<0.05).
Oncotarget39589www.impactjournals.com/oncotarget
with celecoxib resulted in a dose-dependent inhibition 
of the production of VEGF in cell culture media in 
human ovarian cancer cells. In addition, we observed a 
statistically significant decrease in blood vessel density 
in each treatment group, as shown by determining the 
CD31 protein expression in the ovarian tumors from 
the KpB mice. Further review of the mouse ovarian 
cancer tumors showed large areas of central necrosis in 
celecoxib-treated tumors, consistent with an insufficient 
blood supply (data not shown). The decrease in tumor-
associated production of VEGF and blood vessel density 
by celecoxib could be one of the major mechanisms 
by which it reduces angiogenesis and inhibits overall 
ovarian cancer growth in the KpB mouse model
In conclusion, we found that the celecoxib is a 
potent inhibitor of ovarian cancer cell growth in vitro 
and in vivo under different metabolic conditions (obese 
versus non-obese) through different targets (Figure 7). 
Celecoxib is currently being evaluated in clinical trials 
as a potential chemotherapeutic and chemopreventive 
agent for a variety of different cancers, including colon, 
lung, breast and ovarian cancer [20, 25, 26, 56, 57]. 
Celecoxib in combination with carboplatin was well-
tolerated and found to have a promising response rate 
of 28.9% in a heavily pre-treated group of women with 
recurrent ovarian cancer [56]. In addition, there has been 
a randomized, phase 2 clinical trial of celecoxib plus 
docetaxl/carboplatin as first line treatment in ovarian 
cancer patients [57]. In this clinical trial, the addition of 
celecoxib did not seem to improve PFS or OS; however, 
24% of the patients on celecoxib stopped this drug early 
due to skin reactions which may have undermined the 
potential benefit of this treatment [57]. Thus, further 
experimental and clinical studies are warranted to fully 
assess the potential benefit of celecoxib alone or in 
combination with other common therapeutic agents in 
women with ovarian cancer.
MATERIALS AND METHODS
Cell culture and reagents
Three ovarian cancer cell lines, SKOV3, Hey and 
IGROV1, were used for these experiments. SKOV3 cells 
were grown in DMEM/F12 media which was supplemented 
with 10% bovine, 100 units/ml penicillin and 100 ug/ml 
streptomycin under 5% CO2. The Hey and IGROV1 cells 
were grown in RPMI 1640 supplemented with 5% and 
10% fetal bovine serum, 300 mM l-glutamine, 10,000 U/
ml penicillin and 10,000 μg/ml streptomycin under 5% 
CO2. Celecoxib was obtained from Pfizer (Groton, CT). 
MTT, RNase A and RIPA buffer were obtained from Sigma 
(St. Louis, MO). Cleaved caspase 3 activity assay kit was 
bought from AAT Bioquest (Sunnyvale, CA). The ChemoTx 
invasion kit was from NeuroProbe (Gaithersburg, MD). 
Enhanced chemiluminescence Western immunoblotting 
detection reagents were obtained from Amersham (Arlington 
Heights, IL). All other chemicals were obtained from Sigma 
(St. Louis, MO).
Cell proliferation assays
The SKOV3, Hey and IGROV1 cells were plated 
in 96-well plates at a concentration of 5000 cells/well 
for 24 hours. These cells were then treated with various 
concentrations of celecoxib for a period of 24-72 hours. 
After the addition of MTT dye (5 mg/mL), the 96-well 
plates were incubated for 1-2 hours at 37°C. 100 uL of 
DMSO was added to the plates in order to terminate the 
MTT reaction, and the plates were read by measuring 
absorption at 595 nm. The effect of celecoxib was 
calculated as a percentage of control cell growth obtained 
from PBS (1%) treated cells grown in the same 96-well 
plates. Each experiment was repeated three times to assess 
for consistency of results.
Figure 7: Schematic presentation of the action of celecoxib in ovarian cancer. Celecoxib inhibited COX-2 activity and reduced 
products of prostaglandins, finally resulted in inhibition of cell proliferation and hTERT RNA expression, induction of apoptosis and cell 
cycle G1 arrest, reduction of cell invasion and in ovarian cancer.
Oncotarget39590www.impactjournals.com/oncotarget
Flow cytometry
The three ovarian cancer cell lines were plated at 
2.5-3.5 x 105 cells/well in 6-well plates in the appropriate 
media for 24 hours. The cells were then treated with 
celecoxib at varying concentrations for 24 hours. After 
treatment, the cells were washed twice with PBS, fixed in 
90% methanol solution and were then stored in a −20°C 
freezer until analysis. The cells were washed twice with 
cold PBS, centrifuged, suspended in 100 uL PBS and 10 
uL of RNase A solution (250 ug/mL) and then incubated 
for 30 minutes at 37°C. After incubation, 110 uL of PI (100 
ug/mL) stain was added to each tube and incubated for 30 
minutes at 4°C. Flow cytometric analysis was conducted 
using a CyAn flow cytometer (Beckman Coulter, Miami, 
FL). ModFit (Verity Software House, Topsham, ME) 
was utilized for the analysis to control for dead cells and 
debris. The experiments were performed in triplicate and 
repeated twice to assess for consistency of response.
Caspase-3 activity assay
Cleaved caspase-3 activity was assessed using 
cleaved caspase-3 activity assay kit. After treating the 
cells with celecoxib in 96-well plates, 10 ul of caspase-3 
assay loading buffer was added into each well and mixed 
gently. The plates were then incubated for 60 min at 37 
°C, 5% CO2. The fluorescence intensity was measured 
at an excitation wavelength of 350 nm and an emission 
wavelength of 450 nm using a plate reader from Tecan 
(Morrisville, NC). Each experiment was repeated at least 
twice for consistency of response.
Real-time RT-PCR for hTERT
Analysis of the effect of celecoxib on hTERT gene 
expression was conducted using real time RT-PCR. Total 
RNA was extracted from the three ovarian cancer cell 
lines using the RNAqueous kit (Ambion, Austin, TX) and 
further purified by the DNA-free kit (Ambion). The reverse 
transcription and PCR reactions were performed using 
the TaqMan Gold one step RT-PCR kit in the ABI Prism 
7700 Sequence Detection System (Applied Biosystems, 
Foster City, CA). Reverse transcription was carried out at 
48°C for 30 minutes. The PCR conditions consisted of a 
10 minute step at 95°C, 40 cycles at 95°C for 15 seconds 
each and 1 minute at 65°C. The housekeeping control 
gene, acidic ribosomal phosphoprotein P0 (RPLP0), was 
used as an internal control to correct for differences in 
the amount of RNA in each sample. The standard curve 
for hTERT was generated by using dilutions of a known 
amount of cRNA synthesized by in vitro transcription of a 
cloned fragment. The normalized level of hTERT in each 
sample was estimated by a ratio of the hTERT level to 
the RPLP0 level [31]. Each experiment was performed in 
triplicate and repeated twice to assess for consistency of 
results.
Western immunoblotting
The SKOV3, Hey and IGROV1 cells were plated 
at 2-4 x 105 cells/well in 6-well plates in their appropriate 
media and were treated for 24 hours with celecoxib. Cell 
lysates were prepared in RIPA buffer (1% NP40, 0.5 
sodium deoxycholate and 0.1% SDS) plus PhosStop. 
Equal amounts of protein were separated by gel 
electrophoresis and transferred onto a PVDF membrane. 
The membrane was blocked with 5% nonfat dry milk and 
then incubated with a 1:1000 dilution of primary antibody 
overnight at 4°C. The membrane was then washed 
and incubated with a secondary peroxidase conjugated 
antibody for 1 hour. Antibody binding was detected using 
an enhanced chemiluminescence detection buffer and 
the Alpha Innotech imaging system (San Leandro, CA). 
After developing, the membrane was re-probed using 
an antibody against α-tubulin or β-actin as a control. 
Each experiment was repeated three times to assess for 
consistency of results.
Prostaglandin E2 (PGE2) assay
The ovarian cancer cell lines were plated in 24 
well plates and cultured for 24 hours. The cells were then 
treated with celecoxib for 18 hours. The culture media was 
harvested using a syringe and filtered through a 0.22-mm 
filter (Millipore, Billerica, MA). PGE2 productions in 
the media was determined by quantitative enzyme-linked 
immunosorbent assay (ELISA) (Cayman Chemical, Ann 
Arbor, MI), according to the manufacturer’s instructions. 
PGE2 concentration was measured in triplicate for each 
cell line. The concentration of PGE2 in the serum of mice 
treated with celecoxib was also assessed by this technique.
Adhesion assay
96-well plates were used, and each well was coated 
with 100 uL laminin-1 and incubated at 37°C for 1 hour. 
The coating was then aspirated, and 200 uL of blocking 
buffer was added to each well and incubated for 45-60 
minutes at 37°C. PBS was used to wash the wells and 
the plates were chilled on ice. To each well, 2.5 x 103 
cells were added with PBS and varying concentrations 
of celecoxib, and the plates were incubated at 37°C for 
2 hours. The media was then aspirated, and the cells 
were fixed by adding 100 uL of 5% glutaraldehyde and 
incubating for 30 minutes at room temperature. Adhered 
cells were washed with PBS and stained with 100 uL of 
10% of crystal violet for 10-30 minutes. The cells were 
then washed repeatedly with sterile water, and 100 uL 
of 10% acetic acid was added to each well to solubilize 
the dye. After 5 minutes of shaking, the absorbance was 
measured at 570 nm using a FLUOstar OMEGA plate 
reader from BMG Labtech (Cary, NC). The experiments 
were repeated three times to assess for consistency of 
results.
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Invasion assay
The ChemoTx invasion kit (Gaithersburg, MD) 
was used to assess invasion in all three ovarian cancer 
cell lines. The cells were placed in a serum free media 
for a period of 24 hours. The cells were then collected, 
washed and re-suspended in Gey’s Balanced Salt 
Solution + 1% BSA, with varying concentrations of 
celecoxib. To each well, 299 uL of media plus varying 
concentrations of celecoxib was added, and the framed 
filter membrane was carefully fitted to the top of the 
plate. The plate was then incubated for 4 hours at 37°C 
to allow invasion into the lower compartment. 3 uL of 
MTT (5 mg/ml) was used to stain these cells at 37°C for 
one hour. The liquid was aspirated, and the wells washed 
with PBS. The MTT dye was solubilized using 200 uL 
of DMSO. The absorbance was measured at 595 nM 
using a FLUOstar OMEGA plate reader (BMG Labtech, 
Cary, NC).
Measurement of VEGF levels
To measure VEGF levels, the SKOV3, Hey and 
IGROV1 cell lines (2.5×105 cells) were plated in 6-well 
plates and incubated under standard culture conditions 
overnight. Subsequently, the media was replaced by serum-
free culture media, and varying concentrations of celecoxib 
were added. The media was collected after 24 hours of 
exposure to celecoxib. 10-50 ul of culture media was used 
to measure the levels of VEGF with a VEGF ELISA kit 
(DVE00, R&D Systems, Minneapolis, MN), according to 
the manufacturer’s instructions. The optical density at 570 
nm of each well was measured using a FLUOstar OMEGA 
reader (Cary, NC). The VEGF concentration in the serum 
of mice after exposure to celecoxib was also measured by 
the same VEGF ELISA kit.
Obesity and the K18-gT121+/-;p53fl/fl; Brca1fl/fl 
mouse model
The K18-gT121
+/-;p53fl/fl;Brca1fl/fl (KpB) mouse model 
(Terry Van Dyke, PhD, NCI) is a serous OC mouse model, 
wherein the tumor suppressor genes, Brca1 and p53 are 
specifically and somatically deleted and the retinoblastoma 
(Rb) proteins are inactivated in the adult ovarian surface 
epithelium [58]. Inactivation of all 3 Rb proteins by T121 
(a fragment of the SV40 large T antigen) is driven by the 
keratin 18 (K18) promoter [58]. Expression of the T121 
transgene and knockout of p53 and Brca1 are conditional 
and only activated via injection of an adenoviral vector 
expressing Cre (AdCre) into the ovarian bursa cavity of 
adult female mice. At approximately 6 months after AdCre 
injection, tumors develop in the affected ovary, while the 
un-injected ovary remains normal.
All experimental animals were maintained in 
accordance with the Institutional Animal Care and 
Use Committee (IACUC) and the NIH guide for the 
Care and Use of Laboratory Animals. Recombinant 
adenovirus Ad5-CMV-Cre (AdCre) was purchased 
from the University of Iowa Transfer Vector Core at a 
titer of 1011–1012 infectious particles/ml. To maximize 
weight gain, mice were provided a high-fat diet (HFD, 
obese group) (60% kcal from fat, Research Diets, New 
Brunswick, NJ) and control mice (non-obese group) 
were provided a low-fat diet (LFD) (10% kcal from 
fat, Research Diets, New Brunswick, NJ) ad libitum, 
beginning at 3 weeks of age [59]. AdCre injection 
occurred at 6 weeks to induce OC [58]. Thirty-
six hours following superovulation, the mice were 
anesthetized, and a single 1 cm incision was made on 
the dorsal surface of each mouse. The AdCre was then 
injected via a needle introduced into the oviduct near 
the infundibulum and into the ovarian bursa, and the 
incision was closed.
The KpB mice were monitored weekly by 
palpation for tumor growth. Celecoxib and placebo 
treatment was initiated after palpation of a 1 cm tumor 
in mice on the HFD (obese group) and LFD (non-
obese group) (N = 15 mice per group). Celecoxib was 
dissolved in DMSO at 5 mg/ml, further diluted 10 times 
in 0.5% methylcellulose with 0.025% Tween 80 and 
injected (IP) daily at a dose of 5 mg/kg body weight for 
4 weeks. The tumor sizes were measured once a week 
by palpation. Tumor volume was calculated using the 
following equation: volume (mm3) = a × b2/2, where is 
the largest diameter and b is the smallest diameter. The 
animals were weighed weekly throughout the study. At 
sacrifice, mice were weighed and blood samples were 
taken. Half of the ovarian tumor was snap-frozen and 
stored at −80°C, and the other half was fixed in 10% 
neutral-buffered formalin and paraffin embedded. Mouse 
heart, lungs and kidneys were also harvested, fixed in 
formalin and grossly examined for any suspicious 
lesions before paraffin embedding.
Immunohistochemistry
Five micron paraffin sections of the ovarian tumors 
from the KpB mice were used for immunohistochemical 
analysis. Staining procedures were performed with the 
assistance of the Immunohistochemical Mouse Core 
Facility at the University of North Carolina at Chapel 
Hill. The following primary antibodies were used: Ki-67 
(Cell Signaling, Beverly, MA, 1:800), MMP-9 and CD31 
(Santa Cruz, Santa Cruz, CA, 1:500 and 1:100), cleaved 
caspase-3 (Cell Signaling, Beverly, MA, 1:100) and COX-
2 (Cell Signaling, Beverly, MA, 1:300). Further processing 
was carried out using ABC-Staining Kits (Vector Labs, 
Burlingame, CA) and hematoxylin. Immunochemistry 
slides were scanned, analyzed and scored by Aperio and 
related ImageScope software (Vista, CA).
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Primary culture of human ovarian cancer cells
Five human ovarian tumor specimens were obtained 
from patients undergoing surgery for serous ovarian 
carcinoma at the University of North Carolina at Chapel 
Hill. The protocol was reviewed and exemption granted 
by the Institutional Review Board at the University of 
North Carolina at Chapel Hill. For the culture of primary 
ovarian cancer cells, the freshly obtained tissues were 
washed three times with Hank’s Buffered Salt Solution 
(HBSS), and then gently minced by scissors in DMEM/
F12 media containing 10% fetal bovine serum (FBS). 
These tissues were then digested in 0.2% collagenase IA, 
100 U/ml penicillin and anti-anti for 30-60 min hours at 
37°C water bath with shaking. After two centrifugations 
with PBS solution, cells were re-suspended and diluted to 
1×105 cells/ml with DMEM/F12 media. 1×104 cells/well 
were then seeded into 96-well plates and incubated for 24 
hours before celecoxib treatment. Cell proliferation was 
measured with MTT assay 72 hours after treatment.
Statistical analysis
All of the experiments were repeated a minimum 
of three times. Data were presented as mean ± S.E.M. 
Statistical analyses of the differences between the groups 
were determined with the two-sided unpaired Student’s 
t-test using GraphPad software (La Jolla, CA USA), and a 
value of p<0.05 was considered as significant.
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